Oral Fluid–Based Biomarkers of Alveolar Bone Loss in Periodontitis by Kinney, Janet S. et al.
Oral Fluid–Based Biomarkers of
Alveolar Bone Loss in Periodontitis
JANET S. KINNEY,a CHRISTOPH A. RAMSEIER,a
AND WILLIAM V. GIANNOBILEa,b
aDepartment of Periodontics and Oral Medicine and Michigan Center for Oral
Health Research, University of Michigan, Ann Arbor, Michigan, USA
bDepartment of Biomedical Engineering, College of Engineering, University of
Michigan, Ann Arbor, Michigan, USA
ABSTRACT: Periodontal disease is a bacteria-induced chronic inflamma-
tory disease affecting the soft and hard supporting structures encom-
passing the teeth. When left untreated, the ultimate outcome is alveolar
bone loss and exfoliation of the involved teeth. Traditional periodontal
diagnostic methods include assessment of clinical parameters and radio-
graphs. Though efficient, these conventional techniques are inherently
limited in that only a historical perspective, not current appraisal, of dis-
ease status can be determined. Advances in the use of oral fluids as pos-
sible biological samples for objective measures of current disease state,
treatment monitoring, and prognostic indicators have boosted saliva and
other oral-based fluids to the forefront of technology. Oral fluids contain
locally and systemically derived mediators of periodontal disease, in-
cluding microbial, host-response, and bone-specific resorptive markers.
Although most biomarkers in oral fluids represent inflammatory me-
diators, several specific collagen degradation and bone turnover-related
molecules have emerged as possible measures of periodontal disease ac-
tivity. Pyridinoline cross-linked carboxyterminal telopeptide (ICTP), for
example, has been highly correlated with clinical features of the disease
and decreases in response to intervention therapies, and has been shown
to possess predictive properties for possible future disease activity. One
foreseeable benefit of an oral fluid–based periodontal diagnostic would
be identification of highly susceptible individuals prior to overt disease.
Timely detection and diagnosis of disease may significantly affect the
clinical management of periodontal patients by offering earlier, less in-
vasive, and more cost-effective treatment therapies.
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PERIODONTAL DISEASES: BACKGROUND
Chronic infectious diseases of the oral cavity include dental caries and pe-
riodontal disease, the former causing destruction of the teeth, while the latter
is, a group of inflammatory conditions, affects the supporting structures of
the dentition.1 The unequivocal role of the microbial challenge in the etiology
of periodontal disease has been well studied. However, it is the paradoxical
impact of the susceptible host’s inflammatory response to the microbial chal-
lenge that ultimately leads to the destruction of the periodontal structures and
subsequent tooth loss.2–4
Periodontal diseases are further divided into reversible and nonreversible
categories. Gingivitis is a reversible inflammatory reaction of the marginal
gingiva to dental plaque biofilms. Gingivitis is characterized by an initial
increase in blood flow, enhanced vascular permeability, and influx of cells
(polymorphonuclear leukocytes [PMNs] and monocyte-macrophages) from
the peripheral blood into the periodontal connective tissue. Overt soft tissue
alterations during the state of gingivitis include redness, edema, bleeding, and
tenderness. The feature distinguishing gingivitis from the destructive form of
periodontal disease is the intact anatomical location of the junctional epithe-
lium on the root surface.
Periodontitis, the destructive category of periodontal disease, is a nonre-
versible inflammatory state of the supporting structures. After its initiation,
the disease progresses with the loss of collagen fibers and attachment to the
cemental surface, apical migration of the pocket epithelium, formation of deep-
ened periodontal pockets, and the resorption of alveolar bone. If left untreated,
the disease continues to progressive bone destruction, leading to tooth mobility
and subsequent tooth loss.5
Chronic periodontitis is the most prevalent form of destructive periodontal
disease and typically progresses at a slow, steady pace with bouts of extensive
disease destruction separated by quiescent periods of bone loss.6–8 Albandar
et al. examined the prevalence and severity of chronic periodontitis in the
United States adult population (30 years and older) and found that from 1988
to 1994 approximately 35% presented with chronic periodontitis. After ad-
justing for measurement error due to the partial readings, it was determined
that approximately half of U.S. adults had chronic periodontitis. Further break-
down of these findings indicate that 31% of the U.S. population exhibit mild
forms of the disease, 13% display moderate severity, and 4% suffer advanced
disease.9,10
More than 600 different bacteria are capable of colonizing the human mouth
with any individual typically harboring 150 to 200 varying species. Of these
many bacteria, it is estimated that approximately 10% play a causal role
in the initiation of periodontal disease.2,11–13 Three organisms in particular,
Tanerella forsythensis, Porphyromonas gingivalis, and Treponema denticola
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have been directly associated with chronic periodontitis.13–15 Actinobacillus
actinomycetemcomitans, another virulent gram-negative bacterium, has been
observed in early-onset forms of periodontal disease and aggressive periodon-
titis.12 Inherent virulence factors of these pathogenic species enable the bac-
teria to colonize on the tooth and in the gingival sulcus, defend itself from the
host’s antibacterial defense mechanisms, and cause tissue damage by produc-
ing potent substances that subsequently trigger the host’s innate inflammatory
response.16 Although pathogen-based diagnostic tests are imperative for the
initiation of periodontal disease, their utility has not been successful for predic-
tion of periodontal disease.17 At best, pathogen-based tests serve as adjuncts
to traditional diagnostic methods by assessing vulnerability of patient and site,
classifying disease category, and assisting in treatment modality.
NEED FOR A PERIODONTAL
DIAGNOSTIC INDICATOR
A periodontal diagnostic tool provides pertinent information for differential
diagnosis, localization of disease, and severity of infection. These diagnostics,
in turn, serve as a basis for planning treatment and provide a means for as-
sessing the effectiveness of periodontal therapy.18 Current clinical diagnostic
parameters that were introduced more than 50 years ago continue to function
as the basic model for periodontal diagnosis in clinical practice today. They
include probing pocket depths, bleeding on probing, clinical attachment levels,
plaque index, and radiographs that quantify alveolar bone levels.19,20 Albeit
easy to use, cost-effective, and relatively noninvasive, clinical attachment loss
evaluation by the periodontal probe measures damage from past episodes of
destruction and requires a 2- to 3-mm threshold change before a site can
be deemed as having experienced significant breakdown. Recent revisions in
the design of automated periodontal probes have improved the accuracy and
long-term tracking of disease progression. Furthermore, the use of subtrac-
tion radiography also offers a method to detect minute changes in the height
of alveolar bone. However, both of the above-mentioned techniques are most
often seen in the research setting and seldom in clinical practice. In addition to
these limitations, conventional disease diagnosis techniques lack the capacity
to identify highly susceptible patients who are at risk for future breakdown.21–23
Researchers are confronted then with the need for an innovative diagnostic test
that focuses on the early recognition of the microbial challenge to the host.
Optimal innovative approaches would correctly determine the presence of cur-
rent disease activity, predict sites vulnerable for future breakdown, and assess
the response to periodontal interventions. A new paradigm for periodontal di-
agnosis would ultimately affect improved clinical management of periodontal
patients.
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ORAL FLUID BIOMARKERS
OF PERIODONTAL DISEASE
In response to requests from the Office of the Surgeon General and the
National Institute of Dental and Craniofacial Research (NIDCR) for concen-
trated research in salivary diagnostics, significant advancements have been
achieved within the past 10 years using saliva, gingival crevicular fluid (GCF),
and mucosal transudate as biological samples for the detection of oral and sys-
temic illnesses.24 Easily collected and containing local- and systemic-derived
biomarkers of periodontal disease, oral fluids may offer the basis for a patient-
specific diagnostic test for periodontal disease.25–28 A biomarker is an objective
measure that has been evaluated and confirmed either as an indicator of physio-
logic health, a pathogenic process, or a pharmacologic response to a therapeutic
intervention.29 Oral fluid biomarkers that have been studied for periodontal di-
agnosis include proteins of host origin (e.g., enzymes and immunoglobulins),
phenotypic markers, host cells (e.g., PMNs), hormones, bacteria and bacte-
rial products, ions, and volatile compounds.20,25,30–32 Because of the complex,
multifaceted nature of periodontal disease, it is highly unlikely that a single
biomarker will prove to be a stand-alone measure for periodontal disease diag-
nosis. More probable may be the development of an oral fluid-based diagnostic
using a combination of host- and site-specific markers that accurately assess
periodontal disease status.31,33–36
During the initiation of an inflammatory response in the periodontal con-
nective tissue (FIG. 1), numerous cytokines, such as prostaglandin E2 (PGE2),
interleukin (IL)-1, IL-6, or tumor necrosis factor (TNF)- are released from
cells of the junctional epithelia, connective tissue fibroblasts, macrophages,
and PMNs. Subsequently, T and B cells emerge at the infection sites and
secrete immunoglobulins as an antigen-specific response.37 Additionally, a
number of enzymes, such as matrix metalloproteinase (MMP)-8, MMP-9, or
MMP-13 are produced by PMNs and osteoclasts, leading to the degradation
of connective tissue collagen and alveolar bone.38 As a consequence of bone
resorption, pyridinoline cross-linked carboxyterminal telopeptide (ICTP) and
osteocalcin are released into the periodontal tissues. During the inflammatory
process intercellular products are created and migrate toward the gingival sul-
cus or periodontal pocket (FIG.1). These mediators of disease activity have
been identified and sampled from various biological fluids, such as saliva and
GCF.39
GCF is an inflammatory exudate originating from the gingival plexus of
blood vessels in the gingival corium, subjacent to the epithelium lining of the
dentogingival space. As GCF traverses through inflamed periodontal tissues
en route to the sulcus, biological molecular markers are gathered from the
surrounding site.40 GCF sampling methods have been shown to accurately
capture inflammatory and connective tissue breakdown mediators.31,33 As re-
cently reviewed by Loos and Tjoa, more than 90 different components in GCF
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FIGURE 1. Schematic overview of the pathogenic processes in periodontal disease.
Initial events are triggered by LPS from gram-negative plaque biofilms on the tooth root
surfaces. As a first line of defense, PMNs are recruited to the site. Monocytes and activated
macrophages respond to endotoxin by releasing cytokines TNF and IL-1, which direct
further destructive processes. MMP, powerful collagen-destroying enzymes, are produced
by fibroblasts and PMNs. TNF, IL-1, and receptor activator of NF-B ligand (RANKL) are
elevated in active sites and mediate osteoclastogenesis and bone breakdown. Bone-specific
markers, such as pyridinoline cross-linked carboxyterminal telopeptide of type I collagen
(ICTP), are released into the surrounding area and transported by way of GCF into the
sulcus or pocket and serve as potential biomarkers for periodontal disease detection.
have been evaluated to date for periodontal diagnosis.41 Of the numerous con-
stituents in GCF, however, the vast majority constitute soft tissue inflammatory
events, while only a few are regarded as specific biomarkers of alveolar bone
destruction (TABLE 1).
In the early 1970s several researchers demonstrated a correlation between
collagenolytic activity of GCF and severity of periodontal disease.42–45 Golub
et al. and co-workers discovered that collagenase activity was more highly
correlated with pocket depth than with inflammation and therefore “may re-
flect the degradative activity of the gingival tissues lining the pocket and
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TABLE 1. Bone-related biomarkers from oral fluids associated with periodontal diseases
Name Association Reference
ALP T 32,34,62,64–66
Cathepsin B S, T 68–72
Collagenase-2 (MMP-8) S, T 79,81,83–89
Gelatinase (MMP-9) T 90
Collagenase-3 (MMP-13) T 79,87
Calprotectin S 98
Osteocalcin S 34,53,79,102–104
Pyridinoline cross-links (ICTP) S, T 79,102,109–116
Osteonectin S 119
Osteopontin S 128,129
NOTE: Association with severity of periodontal disease (S) and treatment planning and outcome (T).
could, therefore, be of diagnostic value.”42 Villela and Birkedal-Hansen also
observed a connection between collagenolytic activity and active disease.46 As
a result from these early observations, thought was given to the possible use
of collagenases as plausible biochemical markers for disease progression.
Prostaglandins are arachidonic acid metabolites composed of 10 classes,
of which D, E, F, G, H, and I are of main importance. Of this group, PGE2
is one of the most extensively studied mediators of periodontal disease ac-
tivity.47–52 During the host’s innate defense response to bacterial lipopolysac-
charide (LPS), monocytes, PMNs, macrophages, and other cells release IL-1,
TNF, and PGE2. PGE2 acts as a potent vasodilator and increases capillary
permeability, which elicits clinical signs of redness and edema. PGE2 also
stimulates fibroblasts and osteoclasts to increase production of MMPs. Ulti-
mately, MMPs affect the remodeling and degradation of the periodontium.33
Offenbacher and co-workers demonstrated that patients with periodontitis had
higher levels of GCF-PGE2 than patients with gingivitis.53,54 This group sub-
sequently performed a retrospective analysis of GCF-PGE2 by examining the
longitudinal relationship of PGE2 concentrations in GCF to attachment loss
in adult patients with periodontitis. Results showed that elevated PGE2 was
detectable in GCF 6 months before the identification of periodontal disease
activity and significantly decreased 1 month after scaling and root planing
was provided.55 Although PGE2 has shown much promise as a biomarker of
periodontitis, PGE2-based diagnostics have not entered the clinical arena.
Another oral fluid that has recently gained significant recognition is saliva.
Technologies are emerging that use minute amounts of saliva as reliable diag-
nostic fluids for identification, monitoring, and prediction of various diseases.
Saliva-based diagnostic tests are currently being used in a broad range of ap-
plications, such as autoimmune disorders, cardiovascular disease, infectious
diseases, and in monitoring drugs of abuse.24 Much work is currently under
way in the field of salivary diagnostics for periodontal disease. Pederson et al.
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measured quantities of host-response indicators—cathepsin G, elastase, elas-
tase inhibitors, and C-reactive protein (CRPs)—to determine whether their
levels were directly related to the individual’s periodontal status. Forty-five
participants were categorized according to periodontal status (healthy, gingivi-
tis, mild-to-moderate periodontitis, or moderate-to-severe periodontitis) and
whole-saliva samples were collected. With the exception of 1-antitrypsin,
an increase in salivary levels for all of the targeted host-response markers
correlated with increasing severity of disease.56 Other early saliva-based in-
vestigations detected significantly increased levels of collagenase 2 (MMP-8)
in periodontally diseased patients.57 Subsequent explorations of immunoglob-
ulins found in whole saliva directed against periodontal pathogens have indi-
cated some correlations with the status of periodontal disease.58–61 Although
saliva-based clinical testing shows much potential, more-extensive research
is required to identify the best candidate markers that can be simultaneously
evaluated to obtain a profile for diagnosis, monitoring, and prediction of oral
diseases.
BIOMARKERS OF BONE RESORPTION
OR TURNOVER
Several biomarkers have been studied as applicable to the diagnostics of
periodontal bone loss (TABLE 1). These components, which are evaluated next,
are the potential candidates for oral fluid–based diagnostics of periodontal
disease.
Alkaline Phosphatase (ALP)
Enzymes found in whole saliva originate from three main sources: (1) the
actual salivary secretions per se; (2) the GCF, stemming from PMNs and
tissue degradation; and (3) disposed bacterial cells from dental biofilms and
mucosal surfaces. ALP is a catalyzing enzyme that accelerates the removal of
phosphate groups in the 5 and 3 positions from a variety of molecules, including
nucleotides, proteins, and alkaloids. Although present in all tissues, ALP is
particularly concentrated in the bone, liver, bile duct, kidney, and placenta. Of
interest in oral health, of course, is the association between ALP and periodontal
disease.
Early investigations of ALP and periodontal disease in an experimental gin-
givitis model showed a significant correlation between ALP and pocket depth
and between ALP and inflammation.62 Nakamura and Slots studied a total of
76 enzyme activities in mixed whole saliva and noted higher enzyme activity
in individuals with periodontal disease than nondiseased individuals.32 Gibert
et al. analyzed serum levels of ALP from patients with chronic periodontal
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disease and compared the findings with those of control patients.63 Results
showed a relationship between attachment loss in the periodontal group and
a drop in ALP activity in serum. Contrary to these results, Totan et al. inves-
tigated the influence of periodontal disease on ALP, aminotransferase (AST),
aminopeptidase, and glucuronidase.64 Salivary samples from patients with
confirmed periodontal disease were analyzed and revealed that periodontal
destruction by measurement of probing depth, gingival bleeding, and suppu-
ration were related to higher ALP levels in saliva. Supporting these results
are the findings by Todorovic et al. that increased activity of salivary ALP is
seen in patients with periodontal disease in relation to a nondisease control
group.65 This group further showed a positive correlation between the salivary
enzyme activity and gingival index values. As a predictive indicator for future
periodontal breakdown, ALP has not been supported by research findings and
therefore may best serve as a marker in periodontal treatment planning and
monitoring.34,66
Cathepsin B
As an enzyme belonging to the class of cysteine proteinases, cathepsin
B functions in proteolysis. In GCF, macrophages are the main producers of
cathepsin B.67 GCF concentrations of cathepsin B were found to be elevated
in patients with periodontal disease, but lower in patients with gingivitis.68
Ichimaru et al. concluded that cathepsin B may be correlated with the severity
of periodontitis.69 Further investigators have shown positive correlations be-
tween cathepin B levels and the severity of periodontal disease, while noting
a reduction of cathepsin B levels after periodontal intervention therapies were
provided.70,71 Eley and Cox studied cathepsin B and evaluated its use as a
predictor of attachment loss.72 Forty-nine patients were monitored after initial
periodontal therapy for 2 years. A total of 121 sites were found with attachment
loss (90 with rapid loss and 31 with gradual loss). Cathepsin B levels were
higher in the sites with rapid loss than in the paired control sites. Moreover, in
the sites with gradual attachment loss, cathepsin B levels were elevated when
compared with the paired control sites. With a cut-off value of 7.5 U/30 sec
GCF sample for the total cathepsin B activity and 30 U/uL for enzyme con-
centration, remarkable results of 100% sensitivity and 99.8% specificity for
both cathepsin B parameters were reported. Cathepsin B may have a potential
use in distinguishing periodontitis from gingivitis and in planning treatment
and monitoring treatment outcomes.41
Collagenase-2 (MMP-8)
MMPs are host proteinases responsible for both tissue degradation and
remodeling.73–77 During progressive periodontal breakdown, gingival and
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periodontal ligament collagens are cleaved by host cell–derived interstitial
collagenases. One vital interstitial collagenase capable of degrading the triple
helical structures of native types I, II, and III collagens found in alveolar bone
matrix is collagenase-2. Collagenase-2, also referred to as MMP-8, is released
during the maturation of PMNs in the bone marrow. Once produced, it becomes
glycosylated and is prestored in the sub-cellular-specific granules, where it is
subsequently released in large quantities as the PMNs are recruited to a site of
inflammation. Chubinskaya et al. demonstrated the ability of non-neutrophil-
lineage mesenchymal cells, such as human gingival and periodontal ligament
fibroblasts and chondrocytes, to also be able to produce MMP-8.78
MMP-8 is the most prevalent MMP found in diseased periodontal tissue and
GCF.79–81 Nomura et al. found no difference in MMP-8 levels from patients
with periodontal disease when compared to patients with gingivitis.82 From
this early investigation, it was believed that MMP-8 may serve as a proinflam-
matory marker, but not as a discriminating marker for chronic periodontitis
and gingivitis. However, Mancini and co-workers found an 18-fold increase
of MMP-8 in patients experiencing active periodontal tissue breakdown as
compared with patients under stable conditions. Conclusions from this inves-
tigation indicated the potential use of MMP-8 as a screening test for detection
of active disease progression.83 Elevated MMP-8 levels in active disease pro-
gression were observed by Lee et al. in a longitudinal study using patients with
gingivitis, nonprogressive, and progressive periodontitis. The total collagenase
activity was observed to be 50% higher in the disease progression group.81
Golub et al. introduced a 20-mg low-dose doxycycline (LDD) capsule, which
preserved its proteinase-inhibitory ability to suppress connective tissue break-
down, but without antibiotic/antimicrobial capabilities. The group went on to
conduct several studies demonstrating that LDD can function as an MMP by
way of suppressing the collagenase activity in GCF and gingival tissues of pa-
tients with adult periodontitis.84,85 To test the hypothesis that LDD could lower
GCF levels of bone-type collagen fragments, clinical parameters (gingival in-
flammation, pocket depth, and radiographic evidence of bone loss) that pre-
dicted excessive MMP activity in periodontal pockets of 18 adult patients were
evaluated. All patients received supragingival scaling 1 month before the base-
line appointment. At the baseline visit and at the subsequent 1- and 2-month
visits, GCF samples were collected. Conventional clinical measures (gingival
index, plaque index, probing depth, and attachment level) were taken at each
time point in the study. Western blots analyses determined that neutrophil-type
collagenase (MMP-8) was increased in disease and substantially reduced by
approximately 60% during the 2-month protocol of LDD.79 MMP-8 may have
some future value as a diagnostic marker for periodontal disease, an indicator
for disease progression, and as a signal to determine the efficacy of treatment.41
MMP-8 has also been detected in elevated amounts in peri-implant sul-
cular fluid (PISF) from peri-implantitis lesions. Teronen et al. identified
higher collagenase-2 levels in failing dental implants compared to nonmobile
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implants.86 Ma et al. went on to explore for the presence of MMP-8 and
collagenase-3, MMP-13, in peri-implant sulcus fluid. Forty-nine randomly
selected dental implant sites in 13 patients were studied. Implants were cate-
gorized into three groups according to the amount of bone loss in the vertical
dimension: <1 mm, from 1 to 3 mm, or >3 mm. Results from this investiga-
tion showed that both MMP-8 and MMP-13 levels were significantly higher in
the >3 mm bone loss group when compared to the groups that had less bone
loss.87 Additional studies were conducted by Kivela-Rajamaki et al., looking
at MMP-8 levels in combination with laminin-5 and, during a separate study,
with MMP-7. Conclusions drawn from both investigations indicate that ele-
vated levels of MMP-8 can be seen in diseased PISF as compared to healthy
PISF.88,89 Collectively, these findings offer hope for the use of MMP-8 as a
marker for active phase of peri-implant disease. Longitudinal studies are re-
quired to evaluate MMP-8 either alone or in conjunction with other molecular
biomarkers to predict the risk of future disease occurrence and to monitor
treatment interventions.
Gelatinase (MMP-9)
Gelatinase (MMP-9), another member of the collagenase family, is pro-
duced by neutrophils and degrades collagen extracellular ground substance.
In a longitudinal study conducted by Teng et al., patients were asked to rinse
and expectorate, providing subject-based instead of individual site-based GCF
rinse samples.90 When analyzed, a twofold increase in mean MMP-9 levels
was reported in patients with recurrent attachment loss. Once given systemic
metronidazole, mouthrinse samples from patients with initial elevated MMP-9
concentrations markedly dropped. Given these results, future use of MMP-9 in
oral diagnostics may best serve as a guide in periodontal treatment monitoring.
Collagenase-3 (MMP-13)
Collagenase-3, referred to as MMP-13, is another collagenolytic MMP with
an exceptionally wide substrate specificity.91,92 MMP-13 is expressed dur-
ing bone formation and gingival wound healing and at heightened quantities
during pathological tissue destructive states, such as arthritis, chronic ulcers,
atherosclerosis, and several types of malignant tumors.93,94 Uitto et al. ex-
amined MMP-13 in chronically inflamed oral mucosa and found that during
the course of prolonged inflammation undifferentiated epithelial cells produce
significant concentrations of MMP-13.95 Tervaharitiala et al. examined dis-
eased gingival sulcular epithelium of patients with adult periodontitis (AD)
and patients with localized juvenile periodontitis (LJP) for evidence of MMP
and found sulcular epithelium expressing detectible levels of MMP-13, MMP-
8, and MMP-2 in vivo.93 Golub et al. were the first to discover MMP-13 in
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GCF of periodontal patients, albeit in only a small proportion (3–4%) of the
total amount of GCF collagenase. Golub further investigated the effects of
LDD as a MMP inhibitor and found that LDD reduced GCF concentrations of
MMP-13 faster and more efficiently than MMP-8 levels.79 MMP-13 has also
been implicated in peri-implantitis. Ma et al. concluded that elevated levels of
both MMP-13 and MMP-8 correlated with irreversible peri-implant vertical
bone loss around loosening dental implants.87 In the future, MMP-13 may be
useful for diagnosing and monitoring the course of periodontal disease as well
as tracking the efficacy of therapy.
Calprotectin
Calprotectin is a 36-kDa protein composed of a dimeric complex of 8- and
14-kDa subunits. Neutrophils are the primary source of calprotectin although
other cells, such as activated monocytes and macrophages and specific ep-
ithelial cells, are also capable of manufacturing the protein. Calprotectin acts
as a calcium- and zinc-binding protein with both antimicrobial and antifun-
gal activities. Furthermore, calprotectin plays a role in immune regulation
through its ability to inhibit immunoglobulin production and, of particular in-
terest, its role as a proinflammatory protein for neutrophil recruitment and acti-
vation.
Current research is using calprotectin as a marker for medical conditions
such as ulcerative colitis and Crohn’s disease.96,97 In periodontology, Kido
et al. identified calprotectin in GCF and found that GCF concentration lev-
els in patients with periodontal disease were higher than those in GCF from
healthy subjects.98 The expression of calprotectin from inflammatory cells ap-
pears to offer protection of the epithelial cells against binding and invasion by
P. gingivalis. In periodontal disease, calprotectin appears to improve resistance
to P. gingivalis by boosting the barrier protection and innate immune functions
of the gingival epithelium.99
Osteocalcin
Elevated serum osteocalcin levels have been found during periods of rapid
bone turnover, such as osteoporosis, multiple myeloma, and fracture re-
pair.100,101 Therefore, studies have investigated the relationship between GCF
osteocalcin levels and periodontal disease.34,53,79,102–104 Kunimatsu et al. re-
ported a positive correlation between GCF osteocalcin N-terminal peptide
levels and clinical parameters in a cross-sectional study of patients with peri-
odontitis and gingivitis.103 The authors also reported that osteocalcin could not
be detected in patients with gingivitis. In contrast, Nakashima et al. reported
significant GCF osteocalcin levels from both periodontitis and gingivitis pa-
tients.53 Osteocalcin levels were also significantly correlated with pocket depth
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and gingival index scores, as well as GCF levels of ALP and PGE2. In a lon-
gitudinal study of untreated periodontitis patients with ≥1.5 mm attachment
loss during the monitoring period, GCF osteocalcin levels alone were unable to
discriminate between active and inactive sites.34 However, when a combination
of the biochemical markers osteocalcin, collagenase, PGE2, -2 macroglob-
ulin, elastase, and ALP was evaluated, increased diagnostic sensitivity and
specificity values of 80% and 91%, respectively, were reported.34
A longitudinal study using an experimental periodontitis model in beagle
dogs reported a strong correlation between GCF osteocalcin levels and ac-
tive bone turnover as assessed by bone-seeking radiopharmaceutical uptake
(BSRU).102 However, osteocalcin was shown to possess only modest pre-
dictive value for future bone loss measured by computer-assisted digitizing
radiography. Moreover, treatment of chronic periodontitis patients with sub-
anti-microbial doxycycline failed to reduce GCF osteocalcin levels,79 and a
cross-sectional study of periodontitis patients reported no differences in GCF
osteocalcin levels between deep and shallow sites in the same patients.105
Moreover, osteocalcin levels in the GCF during orthodontic tooth movement
were highly variable between subjects and lacked a consistent pattern re-
lated to the stages of tooth movement.106 In summary, the results of these
studies show a role for intact osteocalcin as a bone-specific marker of bone
turnover.
Pyridinoline Cross-Linked Carboxyterminal Telopeptide
of Type I Collagen (ICTP)
Given the specificity and sensitivity for bone resorption, pyridinoline cross-
links represent a potentially valuable diagnostic aid for periodontal disease,
since biomarkers specific for bone degradation may be useful in differentiating
between the presence of gingival inflammation and active periodontal or peri-
implant bone destruction.107 Several investigations have explored the ability
of pyridinoline cross-links to detect bone resorption in periodontitis and peri-
implantitis as well as in response to periodontal therapy.79,102,105,108–116
Palys et al. related ICTP levels to the subgingival microflora of various dis-
ease states on GCF.110 Subjects were divided into groups representing health,
gingivitis, and chronic periodontitis, and GCF and plaque samples were col-
lected from each subject. The samples were analyzed for ICTP levels and the
presence of 40 subgingival species by using checkerboard DNA–DNA hy-
bridization techniques. ICTP levels differed significantly between health, gin-
givitis, and periodontitis subjects, and related modestly to several clinical dis-
ease parameters. ICTP levels were also strongly correlated with whole subject
levels of several periodontal pathogens including T. forsythensis, P. gingivalis,
P. intermedia, and T. denticola. In a subsequent study, Oringer
et al. examined the relationship between ICTP levels and subgingival species
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around implants and teeth in 20 partially edentulous and two fully edentulous
patients. No significant differences were found among ICTP levels and sub-
gingival plaque composition between implants and teeth. Strong correlations
between elevated ICTP levels at implant sites and colonization with organ-
isms associated with failing implants, such as P. intermedia, F. nucleatum ss
vincentii, and S. gordonii were found.109
Golub et al. found that treatment of chronic periodontitis patients with non-
surgical periodontal therapy and LDD resulted in a 70% reduction in GCF
ICTP levels after 1 month, concomitant with a 30% reduction in collagenase
levels.79 An investigation of periodontitis patients treated with scaling and root
planing also demonstrated significant correlations between GCF ICTP levels
and clinical periodontal disease parameters, including attachment loss, pocket
depth, and bleeding on probing.107 In addition, elevated GCF ICTP levels at
baseline, especially at shallow sites, were found to be predictive for future
attachment loss as early as 1 month after sampling. Furthermore, treatment of
a group of periodontitis subjects by SRP and locally delivered minocycline led
to rapid reductions in GCF ICTP levels.79
In summary, studies assessing the role of GCF ICTP levels as a diagnos-
tic marker of periodontal disease activity have produced promising results to
date. ICTP has been shown to be a promising predictor of both future alveolar
bone and attachment loss. Furthermore, ICTP was strongly correlated with
clinical parameters and putative periodontal pathogens, and demonstrated sig-
nificant reductions after periodontal therapy. Controlled human longitudinal
trials are needed to fully establish the role of ICTP as a predictor of periodon-
tal tissue destruction, disease activity, and response to therapy in periodontal
patients.
Therefore, the measurement of connective tissue–derived molecules, such
as ICTP or osteocalcin, may lead to a more accurate assessment of tissue
breakdown.117
Osteonectin
Also referred to as secreted protein acidic and rich in cysteine and base-
ment membrane protein (BM-40), osteonectin is a single-chain polypeptide
that binds strongly to hydroxyapatite and other extracellular matrix proteins
including collagens. Because of its affinity for collagen and hydroxylapatite,
osteonectin has been implicated in the early phases of tissue mineralization.118
In a cross-sectional study by Bowers et al., GCF samples were analyzed from
patients with gingivitis, at moderate or severe periodontal disease states. Using
a dot blot assay, both osteonectin and N-propeptide alpha I type I collagen were
significantly increased in patients with periodontal disease. Furthermore, the
protein concentrations found in GCF were elevated as probe depth measures in-
creased in the sites evaluated.119 At the final analysis of this study, osteonectin
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appeared to be the more sensitive marker for detection of periodontal disease
status, when compared with N-propeptide alpha I type I collagen.
Osteopontin (OPN)
OPN is a single-chain polypeptide having a molecular weight of approxi-
mately 32,600.120 It is found in the kidney, blood, mammary gland, salivary
glands, and bone. In bone matrix, OPN is highly concentrated at sites where
osteoclasts are attached to the underlying mineral surface, that is, the clear
zone attachment areas of the plasma membrane.121,122 However, since OPN
is produced by both osteoblasts and osteoclasts, it holds a dual function in
bone maturation and mineralization as well as bone resorption.123–127 Kido
et al. investigated the presence of OPN in GCF and the correlation between
these levels and probing depth measures of periodontally healthy and diseased
patients. Results from this study revealed that OPN could be detected in GCF,
and increased OPN levels coincided with increased probing depth measures.128
Sharma et al. recently published findings from an investigation of GCF OPN.
A total of 45 subjects were divided into three groups (healthy, gingivitis, and
chronic periodontitis) based on clinical examination, modified gingival in-
dex, Ramfjord periodontal disease index scores, and radiographic evidence of
bone loss. The chronic periodontitis group subsequently received nonsurgical
therapy and GCF samples were collected again 6 to 8 weeks after treatment.
Results indicated that GCF OPN concentrations increased proportionally with
the progression of disease and when nonsurgical periodontal treatment was
provided, GCF OPN levels were significantly reduced. Although additional
long-term prospective studies are needed, at this point OPN appears to hold
promise as a possible biomarker of periodontal disease progression.129
FUTURE DIRECTIONS FOR PERIODONTAL
ORAL FLUID–BASED DIAGNOSTICS
Researchers involved in delivery of periodontal therapy are currently inves-
tigating the possible use of oral fluids in the diagnosis of oral diseases and drug
development. The movement of the pharmaceutical industry toward pharma-
cogenomics will require the tailored design of specific diagnostic profiles of
patients for individualized dental therapy. Professionals in seemingly unrelated
arenas, such as the insurance industry, Environment Protection Agency, and
Homeland Security, are interested in the possibility of oral fluid use as well
for rapid screening of oral and systemic health status.
As it relates to periodontology, the great need for periodontal diagnostics
has become increasingly evident. From physical measurements by periodontal
probing to sophisticated genetic susceptibility analysis and molecular arrays
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for the detection of biomarkers on the different stages of the disease, substantial
improvements have been made in the understanding of the mediators implicated
on the initiation, pathogenesis, and progression of periodontitis. Through the
biomarker discovery process, new therapeutics have been designed linking
therapeutic and diagnostic approaches together, especially in the area of host
modulatory drugs for periodontal disease treatment. Moreover, new diagnostic
technologies, such as microarray and microfluidics, are now currently available
for risk assessment and comprehensive screening of biomarkers. The future
is bright for the use of rapid, easy-to-use diagnostics that will provide an
enhanced patient assessment that can guide and transform customized therapies
for dental patients, leading to more individualized, targeted treatments for oral
health.
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